The estimated Net Worth of Irit Arbel is at least $132 millier dollars as of 28 August 2019. Irit Arbel owns over 13,332 units of Brainstorm Cell Therapeutics stock worth over $47,366 and over the last 19 years he sold BCLI stock worth over $0. In addition, he makes $84,366 as Vice Chairman of the Board at Brainstorm Cell Therapeutics.
Sign up
Irit Arbel BCLI stock SEC Form 4 insiders trading
Irit has made over 2 trades of the Brainstorm Cell Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 13,332 units of BCLI stock worth $29,997 on 28 August 2019.
The largest trade he's ever made was exercising 13,332 units of Brainstorm Cell Therapeutics stock on 28 August 2019 worth over $29,997. On average, Irit trades about 633 units every 29 days since 2005. As of 28 August 2019 he still owns at least 169,165 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Irit Arbel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Irit Arbel biography
Dr. Irit Arbel serves as Vice Chairman of the Board of the Company. Dr. Arbel is the Chairperson of the Board and the Chair of the Governance, Nominating and Compensation Committee. Dr. Arbel serves as CEO of Neurchords, a biotechnology firm developing graphene- based scaffold for nerve reconstruction in acute spinal cord and peripheral nerve injury. Dr. Arbel has been appointed this year as director of the Board of Isracann Biosciences, a medical Cannabis company traded at the CSE in Canada. Dr. Arbel served as Executive Vice President, Research and Development at Savicell Diagnostic Ltd until August 2018. From 2009 through 2011, Dr. Arbel served as Chairperson of Real Aesthetics Ltd., a company specializing in cellulite ultrasound treatment, and BRH Medical, developer of medical devices for wound healing. She was also Director of M&A at RFB Investment House, a private investment firm focusing on early stage technology related companies. Previously, Dr. Arbel was President and Chief Executive Officer of Pluristem Life Systems, a biotechnology company, and prior to that, Israeli Sales Manager of Merck, Sharp & Dohme, a pharmaceutical company. Dr. Arbel earned her Post Doctorate degree in 1997 in Neurobiology, after performing research in the area of Multiple Sclerosis. Dr. Arbel also holds a Chemical Engineering degree from the Technion, Israel's Institute of Technology. Arbel possesses specific attributes that qualify her to serve on our Board including Dr. Arbel’s extensive experience in the biotechnology field and significant leadership skills as a chief executive officer. Dr. Arbel previously served as our President, which service has given her a deep knowledge of the Company and its business and directly relevant management experience.
What is the salary of Irit Arbel?
As the Vice Chairman of the Board of Brainstorm Cell Therapeutics, the total compensation of Irit Arbel at Brainstorm Cell Therapeutics is $84,366. There are 6 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.
How old is Irit Arbel?
Irit Arbel is 60, he's been the Vice Chairman of the Board of Brainstorm Cell Therapeutics since 2020. There are 5 older and 12 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.
What's Irit Arbel's mailing address?
Irit's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Insiders trading at Brainstorm Cell Therapeutics
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger et International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
What does Brainstorm Cell Therapeutics do?
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
What does Brainstorm Cell Therapeutics's logo look like?
Complete history of Irit Arbel stock trades at Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics executives and stock owners
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include:
-
Chaim Lebovits,
Chief Exec. Officer -
Chaim Lebovits,
Chief Executive Officer -
Ralph Kern,
President, Chief Medical Officer -
Dr. Ralph Z. Kern,
Pres & Chief Medical Officer -
Dr. Stacy R. Lindborg Ph.D.,
Exec. VP & Chief Devel. Officer -
Preetam Shah,
Chief Financial Officer, Executive Vice President, Treasurer -
Irit Arbel,
Vice Chairman of the Board -
Malcolm Taub,
Independent Director -
Uri Yablonka,
Executive Vice President, Chief Business Officer, Director -
June Almenoff,
Independent Director -
Anthony Polverino,
Independent Director -
Arturo Araya,
Chief Commercial Officer -
Uri Yablonka,
Exec. VP, Chief Bus. Officer, Sec. & Director -
Dr. Irit Arbel DSc, Ph.D.,
Co-Founder & Independent Vice Chair of the Board -
Dr. Irit Arbel Ph.D., DSc,
Co-Founder & Independent Vice Chair of the Board -
Sankesh Abbhi,
Director -
Anthony Waclawski,
Executive Vice President - Global Head of Regulatory Affairs -
Stacy Lindborg,
Executive Vice President Head of Global Clinical Research -
David Setboun,
Chief Operating Officer, Executive Vice President -
Jacob Frenkel,
Chairman of the Board -
Antal Pearl-Lendner,
VP & Chief Legal Counsel -
Alla Patlis CPA, M.B.A.,
Controller & Interim CFO -
William K. White,
Sr. VP & Head of Market Access and Pricing -
Dr. Daniel Offen,
Chief Scientific Advisor -
Dr. Yael Gothelf,
VP of Scientific & Regulatory Affairs -
Dr. David Setboun M.B.A., Pharm.D.,
Exec. VP & COO -
Dr. Preetam Shah M.B.A., Ph.D.,
Exec. VP, CFO & Treasurer -
Mordechai Friedman,
Director -
International Holdings Ltd....,
-
Alon Pinkas,
Director -
Robert G L Shorr,
Director -
Yoram Bibring,
Chief Financial Officer -
Chen Schor,
Director -
Eyal Rubin,
CFO and Treasurer -
Nir Naor,
Director -
Alla Patlis,
See Remarks -
Anthony S. Fiorino,
Chief Executive Officer -
Liat Sossover,
Chief Financial Officer -
Avi Israeli,
Director -
Adrian Harel,
Acting Chief Executive Officer -
Corp. Accbt,
10% owner -
Aviv University Economic Co...,
10% owner -
Aviv University Tel,
10% owner -
Abraham Efrati,
Chief Executive Officer -
David Stolick,
Chief Financial Officer -
At Tel Aviv University Ltd ...,
10% owner -
Jonathan C Javitt,
Director -
Beck Yaffa,
President and CEO -
Moshe Lion,
Director -
Michael D Greenfield,
Director -
Yoram Drucker,
Chief Operating Officer -
Mike Frankenberger,
-
Kirk Taylor,
Chief Medical Officer -
Hartoun Hartounian,
EVP, Chief Operating Officer -
Ibrahim B. Dagher,
Chief Medical Officer